Health Economics›Hepatocellular carcinoma›Subsequent lines of therapy

Subsequent lines of therapy

Hepatocellular carcinoma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	—	10.2 mo	2	R 303 276 PFS proxy	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	~23.7 mo	~9	~R 707 538 PFS proxy · indirect	1
Lenvatinib monotherapy Variant #01	—	R 27 935	28d	~8.0 mo	~16.0 mo	~2	~R 55 870 PFS proxy · indirect	5
Sorafenib monotherapy Variant #04	—	R 16 002	28d	~3.7 mo	~10.7 mo	~2	~R 32 005 PFS proxy · indirect	33
FOLFOX4 Variant #01	—	R 2 374	14d	—	6.4 mo	3	R 7 122 PFS proxy	1
Doxorubicin monotherapy Variant #01	—	R 902	21d	—	7.0 mo	9	R 8 114 PFS proxy	2
Camrelizumab monotherapy Variant #01 Partial	—	—	14d	—	~8.0 mo	~2	—	1
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	~16.0 mo	~2	—	1
Apatinib monotherapy Variant #01 Partial	—	—	28d	—	8.7 mo	2	—	1
Placebo Partial	—	—	—	2.3 mo	7.7 mo	—	—	13
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	~16.4 mo	~2	—	1

11 of 11 regimens shown